Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

QJM. 2019 Jan 3. doi: 10.1093/qjmed/hcy272. [Epub ahead of print] No abstract available.

PMID:
30605544
2.

Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

Arthritis Rheumatol. 2019 Jan 3. doi: 10.1002/art.40769. [Epub ahead of print] No abstract available.

PMID:
30604506
3.

The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis.

Woodcock HV, Eley JD, Guillotin D, Platé M, Nanthakumar CB, Martufi M, Peace S, Joberty G, Poeckel D, Good RB, Taylor AR, Zinn N, Redding M, Forty EJ, Hynds RE, Swanton C, Karsdal M, Maher TM, Bergamini G, Marshall RP, Blanchard AD, Mercer PF, Chambers RC.

Nat Commun. 2019 Jan 2;10(1):6. doi: 10.1038/s41467-018-07858-8.

4.

Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study.

Nolan CM, Maddocks M, Maher TM, Banya W, Patel S, Barker RE, Jones SE, George P, Cullinan P, Man WD.

Eur Respir J. 2018 Nov 28. pii: 1801186. doi: 10.1183/13993003.01186-2018. [Epub ahead of print]

PMID:
30487200
5.

Predicting outcomes in rheumatoid arthritis related interstitial lung disease.

Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, Bartholmai BJ, van Beek FT, Struik MHL, Stewart GA, Kokosi M, Egashira R, Brun AL, Cross G, Barnett J, Devaraj A, Margaritopoulos G, Karwoski R, Renzoni E, Maher TM, Wells AU.

Eur Respir J. 2019 Jan 3;53(1). pii: 1800869. doi: 10.1183/13993003.00869-2018. Print 2019 Jan.

6.

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.

Richeldi L, Fletcher S, Adamali H, Chaudhuri N, Wiebe S, Wind S, Hohl K, Baker A, Schlenker-Herceg R, Stowasser S, Maher TM.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801060. doi: 10.1183/13993003.01060-2018. Print 2019 Jan.

PMID:
30442716
7.

The Potential Impact of Azithromycin in Idiopathic Pulmonary Fibrosis.

Macaluso C, Furcada JM, Alzaher O, Chaube R, Chua F, Wells AU, Maher TM, George PM, Renzoni EA, Molyneaux PL.

Eur Respir J. 2018 Nov 15. pii: 1800628. doi: 10.1183/13993003.00628-2018. [Epub ahead of print] No abstract available.

PMID:
30442715
8.

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.

Cottin V, Koschel D, Günther A, Albera C, Azuma A, Sköld CM, Tomassetti S, Hormel P, Stauffer JL, Strombom I, Kirchgaessler KU, Maher TM.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00084-2018. doi: 10.1183/23120541.00084-2018. eCollection 2018 Oct.

9.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

10.

PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production.

Celada LJ, Kropski JA, Herazo-Maya JD, Luo W, Creecy A, Abad AT, Chioma OS, Lee G, Hassell NE, Shaginurova GI, Wang Y, Johnson JE, Kerrigan A, Mason WR, Baughman RP, Ayers GD, Bernard GR, Culver DA, Montgomery CG, Maher TM, Molyneaux PL, Noth I, Mutsaers SE, Prele CM, Peebles RS Jr, Newcomb DC, Kaminski N, Blackwell TS, Van Kaer L, Drake WP.

Sci Transl Med. 2018 Sep 26;10(460). pii: eaar8356. doi: 10.1126/scitranslmed.aar8356.

11.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Cottin V.

BMJ Open Respir Res. 2018 Sep 4;5(1):e000289. doi: 10.1136/bmjresp-2018-000289. eCollection 2018.

12.

Regularized Latent Class Model for Joint Analysis of High-Dimensional Longitudinal Biomarkers and a Time-to-Event Outcome.

Sun J, Herazo-Maya JD, Molyneaux PL, Maher TM, Kaminski N, Zhao H.

Biometrics. 2018 Sep 3. doi: 10.1111/biom.12964. [Epub ahead of print]

PMID:
30178494
13.

Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA.

Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28.

PMID:
30170904
14.

Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial.

Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Blahova Z, Wachtlin D, Diefenbach C, Jenkins RG.

BMJ Open Respir Res. 2018 Aug 20;5(1):e000325. doi: 10.1136/bmjresp-2018-000325. eCollection 2018.

15.

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views.

Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, Axmann J, Nathan SD.

Respiration. 2018;96(6):514-524. doi: 10.1159/000490667. Epub 2018 Aug 16.

PMID:
30114692
16.

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis.

Spagnolo P, Kreuter M, Maher TM, Wuyts W, Bonella F, Corte TJ, Kopf S, Weycker D, Kirchgaessler KU, Ryerson CJ.

Respiration. 2018;96(4):314-322. doi: 10.1159/000489668. Epub 2018 Jul 19.

PMID:
30025392
17.

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.

Wu X, Kim GH, Salisbury ML, Barber D, Bartholmai BJ, Brown KK, Conoscenti CS, De Backer J, Flaherty KR, Gruden JF, Hoffman EA, Humphries SM, Jacob J, Maher TM, Raghu G, Richeldi L, Ross BD, Schlenker-Herceg R, Sverzellati N, Wells AU, Martinez FJ, Lynch DA, Goldin J, Walsh SLF.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):12-21. doi: 10.1164/rccm.201803-0444PP. No abstract available.

18.

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use.

Diamantopoulos A, Maher TM, Schoof N, Esser D, LeReun C.

Pharmacoecon Open. 2018 Jun 25. doi: 10.1007/s41669-018-0085-0. [Epub ahead of print]

19.

Could quality be the key in connective tissue disease-associated interstitial lung disease?

Molyneaux PL, Maher TM.

Respirology. 2018 Jun 13. doi: 10.1111/resp.13340. [Epub ahead of print] No abstract available.

PMID:
29897157
20.

Improved quantitation and reproducibility in multi-PET/CT lung studies by combining CT information.

Holman BF, Cuplov V, Millner L, Endozo R, Maher TM, Groves AM, Hutton BF, Thielemans K.

EJNMMI Phys. 2018 Jun 5;5(1):14. doi: 10.1186/s40658-018-0212-0.

21.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.

Maher TM, van der Aar EM, Van de Steen O, Allamassey L, Desrivot J, Dupont S, Fagard L, Ford P, Fieuw A, Wuyts W.

Lancet Respir Med. 2018 Aug;6(8):627-635. doi: 10.1016/S2213-2600(18)30181-4. Epub 2018 May 20.

22.

Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis.

Jacob J, Bartholmai BJ, Rajagopalan S, van Moorsel CHM, van Es HW, van Beek FT, Struik MHL, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Cross G, Barnett J, de Lauretis A, Judge EP, Desai S, Karwoski R, Ourselin S, Renzoni E, Maher TM, Altmann A, Wells AU.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):767-776. doi: 10.1164/rccm.201711-2174OC.

23.

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK.

Strongman H, Kausar I, Maher TM.

Adv Ther. 2018 May;35(5):724-736. doi: 10.1007/s12325-018-0693-1. Epub 2018 Apr 11.

24.

Rapidly Progressive Cystic Lung Disease.

Rogers C, Kent-Bramer J, Devaraj A, Nicholson AG, Molyneaux PL, Wells AU, Saikia S, Maher TM, George PM.

Am J Respir Crit Care Med. 2018 Jul 15;198(2):264. doi: 10.1164/rccm.201801-0161IM. No abstract available.

25.

The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.

Diamantopoulos A, Wright E, Vlahopoulou K, Cornic L, Schoof N, Maher TM.

Pharmacoeconomics. 2018 Jul;36(7):779-807. doi: 10.1007/s40273-018-0631-8. Review.

26.

Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease.

Jacob J, Song JW, Yoon HY, Cross G, Barnett J, Woo WL, Adams F, Kokosi M, Devaraj A, Renzoni E, Maher TM, Kim DS, Wells AU.

EBioMedicine. 2018 Feb;28:303-310. doi: 10.1016/j.ebiom.2018.01.038. Epub 2018 Jan 31.

27.

Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.

Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S, Kolb M.

Respiration. 2018;95(5):317-326. doi: 10.1159/000486286. Epub 2018 Feb 7.

PMID:
29414827
28.

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Wolters PJ, Blackwell TS, Eickelberg O, Loyd JE, Kaminski N, Jenkins G, Maher TM, Molina-Molina M, Noble PW, Raghu G, Richeldi L, Schwarz MI, Selman M, Wuyts WA, Schwartz DA.

Lancet Respir Med. 2018 Feb;6(2):154-160. doi: 10.1016/S2213-2600(18)30007-9. Review.

29.

The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis.

Usmani OS, Biddiscombe MF, Yang S, Meah S, Oballa E, Simpson JK, Fahy WA, Marshall RP, Lukey PT, Maher TM.

Respir Res. 2018 Feb 6;19(1):25. doi: 10.1186/s12931-018-0732-0.

30.

The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.

Hammond M, Clark AB, Cahn AP, Chilvers ER, Fraser WD, Livermore DM, Maher TM, Parfrey H, Swart AM, Stirling S, Thickett D, Whyte M, Wilson A.

Trials. 2018 Feb 5;19(1):89. doi: 10.1186/s13063-018-2453-6.

31.

Diverse functions of clusterin promote and protect against the development of pulmonary fibrosis.

Peix L, Evans IC, Pearce DR, Simpson JK, Maher TM, McAnulty RJ.

Sci Rep. 2018 Jan 30;8(1):1906. doi: 10.1038/s41598-018-20316-1.

32.

Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF).

Win T, Screaton NJ, Porter JC, Ganeshan B, Maher TM, Fraioli F, Endozo R, Shortman RI, Hurrell L, Holman BF, Thielemans K, Rashidnasab A, Hutton BF, Lukey PT, Flynn A, Ell PJ, Groves AM.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):806-815. doi: 10.1007/s00259-017-3917-8. Epub 2018 Jan 16.

33.

Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization.

Keir GJ, Wort SJ, Kokosi M, George PM, Walsh SLF, Jacob J, Price L, Bax S, Renzoni EA, Maher TM, MacDonald P, Hansell DM, Wells AU.

Respirology. 2018 Jul;23(7):687-694. doi: 10.1111/resp.13250. Epub 2018 Jan 12.

PMID:
29327393
34.

Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema.

Jacob J, Bartholmai BJ, Rajagopalan S, Karwoski R, Nair A, Walsh SLF, Barnett J, Cross G, Judge EP, Kokosi M, Renzoni E, Maher TM, Wells AU.

Respirology. 2018 Jun;23(6):593-599. doi: 10.1111/resp.13231. Epub 2017 Dec 13.

35.

Towards a global initiative for fibrosis treatment (GIFT).

Molina-Molina M, Agusti A, Crestani B, Schwartz DA, Königshoff M, Chambers RC, Maher TM, Faner R, Mora AL, Rojas M, Antoniou KM, Sellares J.

ERJ Open Res. 2017 Dec 1;3(4). pii: 00106-2017. doi: 10.1183/23120541.00106-2017. eCollection 2017 Oct.

36.

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.

Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG.

Lancet Respir Med. 2017 Dec;5(12):946-955. doi: 10.1016/S2213-2600(17)30430-7. Epub 2017 Nov 14.

37.

Phenotypic characteristics associated with slow gait speed in idiopathic pulmonary fibrosis.

Nolan CM, Maddocks M, Maher TM, Canavan JL, Jones SE, Barker RE, Patel S, Jacob J, Cullinan P, Man WD.

Respirology. 2018 May;23(5):498-506. doi: 10.1111/resp.13213. Epub 2017 Nov 14.

38.

Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study.

Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, Guillen-Guio B, Ma SF, Okamoto T, John AE, Obeidat M, Yang IV, Henry A, Hubbard RB, Navaratnam V, Saini G, Thompson N, Booth HL, Hart SP, Hill MR, Hirani N, Maher TM, McAnulty RJ, Millar AB, Molyneaux PL, Parfrey H, Rassl DM, Whyte MKB, Fahy WA, Marshall RP, Oballa E, Bossé Y, Nickle DC, Sin DD, Timens W, Shrine N, Sayers I, Hall IP, Noth I, Schwartz DA, Tobin MD, Wain LV, Jenkins RG.

Lancet Respir Med. 2017 Nov;5(11):869-880. doi: 10.1016/S2213-2600(17)30387-9. Epub 2017 Oct 20.

39.

Combination Therapy and the Start of a New Epoch for Idiopathic Pulmonary Fibrosis?

Maher TM.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):283-284. doi: 10.1164/rccm.201709-1939ED. No abstract available.

40.

Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study.

Herazo-Maya JD, Sun J, Molyneaux PL, Li Q, Villalba JA, Tzouvelekis A, Lynn H, Juan-Guardela BM, Risquez C, Osorio JC, Yan X, Michel G, Aurelien N, Lindell KO, Klesen MJ, Moffatt MF, Cookson WO, Zhang Y, Garcia JGN, Noth I, Prasse A, Bar-Joseph Z, Gibson KF, Zhao H, Herzog EL, Rosas IO, Maher TM, Kaminski N.

Lancet Respir Med. 2017 Nov;5(11):857-868. doi: 10.1016/S2213-2600(17)30349-1. Epub 2017 Sep 21.

41.

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.

Birring SS, Wijsenbeek MS, Agrawal S, van den Berg JWK, Stone H, Maher TM, Tutuncu A, Morice AH.

Lancet Respir Med. 2017 Oct;5(10):806-815. doi: 10.1016/S2213-2600(17)30310-7. Epub 2017 Sep 8.

42.

Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.

Maher TM, Molina-Molina M, Russell AM, Bonella F, Jouneau S, Ripamonti E, Axmann J, Vancheri C.

BMC Pulm Med. 2017 Sep 15;17(1):124. doi: 10.1186/s12890-017-0468-5.

43.

Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective study.

Nolan CM, Delogu V, Maddocks M, Patel S, Barker RE, Jones SE, Kon SSC, Maher TM, Cullinan P, Man WD.

Thorax. 2017 Sep 7. pii: thoraxjnl-2017-210589. doi: 10.1136/thoraxjnl-2017-210589. [Epub ahead of print]

PMID:
28883090
44.

Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and Survival.

Khiroya R, Macaluso C, Montero MA, Wells AU, Chua F, Kokosi M, Maher TM, Devaraj A, Rice A, Renzoni EA, Nicholson AG.

Am J Surg Pathol. 2017 Dec;41(12):1683-1689. doi: 10.1097/PAS.0000000000000928.

45.

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017. Print 2017 Aug.

PMID:
28860269
46.

Home spirometry for idiopathic pulmonary fibrosis: ready for prime time?

Maher TM.

Eur Respir J. 2017 Jul 20;50(1). pii: 1701403. doi: 10.1183/13993003.01403-2017. Print 2017 Jul. No abstract available.

47.

Time for an International Consensus on Hypersensitivity Pneumonitis. A Call to Arms.

Molyneaux PL, Maher TM.

Am J Respir Crit Care Med. 2017 Sep 15;196(6):665-666. doi: 10.1164/rccm.201707-1439ED. No abstract available.

PMID:
28723313
48.

Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis.

Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Maher TM, Nair A, Karwoski R, Renzoni E, Walsh SLF, Hansell DM, Wells AU.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700379. doi: 10.1183/13993003.00379-2017. Print 2017 Jul.

49.

Cough in fibrotic lung disease: An unresolved challenge.

Saunders P, Maher TM.

Respirology. 2017 Nov;22(8):1491-1492. doi: 10.1111/resp.13116. Epub 2017 Jul 4. No abstract available.

50.

Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).

Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, Varga J, Coeck C, Gahlemann M, Sauter W, Schmidt H, Highland KB; SENSCIS™ trial investigators.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):75-81. Epub 2017 Jun 29.

Supplemental Content

Loading ...
Support Center